The new strategy of treatment of cognitive impairment
ARTICLE PDF (Українська)


mild cognitive impairment, diagnosis of cognitive deficits, memokor, Extract of Ginkgo biloba, piracetam.

How to Cite

Svyrydova, N. (2015). The new strategy of treatment of cognitive impairment. East European Journal of Neurology, (3(3), 39-43.


The initial manifestation of memory impairment is mild cognitive disorders characterized by mild signs of memory impairment, and / or general cognitive decline in the absence of data for the presence of dementia syndrome and prevent the possibility of cognitive impairment due to any cerebral or systemic disease, organ failure, intoxication (in including medical), depression, or mental retardation. The severity of cognitive deficits in patients with cerebrovascular disease are more correlated not with territorial infarcts caused by the defeat of major cerebral arteries, and on microvascular pathology (a minor heart attack, multiple lacunar infarcts, microbleeds), as well as cerebral atrophy, which may be due to vascular brain damage and specific neurodegenerative process. Since effective therapeutic drugs treat persistent cognitive impairment in the present does not exist, an alternative could be a strategy of weakening the development of cognitive impairment and their progression.
ARTICLE PDF (Українська)


1. Ferri CP, Sousa R, Albanese E, Ribeiro WS, Honyashiki M. The growth of dementia. In: Prince M, Jackson J, editors. World Alzheimer report-2009 Executive summary, Alzheimer Disease International.2010. pp. 1–21.
2. Rasquin SM, Verhey FR, van Oostenbrugge RJ et al. Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Neurosurg Psychiat 2004; 75: 1562–7.
3. Leys D, Неnon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol 2005; p. 752–9.
4. O’Brien JT. Medial temporal atrophy rather than white matter hyperintensivities predict cognitive decline in stroke survivors. VASCOG, San Antonio, 2007; p. 31.
5. Sendrowski K, Sobaniec W, Stasiak-Barmuta A, Sobaniec P, Popko J. Study of the protective effects of nootropic agents against neuronal damage induced by amyloid-beta (fragment 25-35) in cultured hippocampal neurons// Pharmacol Rep. 2015 Apr;67(2):326-31.
6. Renshaw PF, Babb SM, Yurgelun-Todd DA et al. Chronic citicholine (CDP- choline administration alters brain phospholipid metabolites and improves cognitive performance in healthy, older adults. 37th ACNP Annual Meeting: Puerto Rico, 1998.
7. Agarwal A, Malini S, Bairy K, Rao M. Effect of Tinospora cordifolia on learning and memory in normal and memory deficit rats. Indian JPharmacol. 2002;34:339–49.
8. Vogel HG. Drug effects on learning and memory. In: Vogel WH, Schlkens BA, Sandow J, Muller G, Vogel WF, editors. Drug Discovery and Evaluation: Pharmacological Assays. 2nd ed. Berlin, Germany: Springer; 2002. pp. 595–643.
9. Agrawal R, Tyagi E, Saxena G, Nath C. Cholinergic influence on memory stages: A study on scopolamine amnesic mice. Indian J Pharmacol. 2009;41:192–6.
10. Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Phytother Res. 1999;13:275–91.
11. Panchabhai TS, Kulkarni UP, Rege NN. Validation of therapeutic claims of Tinospora cordifolia: A review. Phytother Res. 2008;22:425–41.
12. Balaraman R, Shingala J. Molecule of the millennium: Nootropics. Indian J Pharmacol. 2002;34:439–40.
13. 13) Upadhyay AK, Kumar K, Kumar A, Mishra HS. Tinosporacordifolia (Willd.) Hook. f. and Thoms. (Guduchi)- validation of the Ayurvedic pharmacology through experimental and clinical studies. Int J Ayurveda Res. 2010;1:112–21.
14. Pattanayak P, Behera P, Das D, Panda S. Ocimum sanctum Linn. A reservoir plant for therapeutic applications: An overview. Pharmacogn Rev. 2010;4:95– 105.
15. Mediratta PK, Sharma KK, Singh S. Evaluation of immunomodulatory potential of Ocimum sanctumseed oil and its possible mechanism of action. J Ethnopharmacol. 2002;80:15–20.
16. Min-Kyung Choo, Eun-Kyung Park, Hae-Kyung Yoon, Dong-Hyun Kim. Antithrombotic and Antiallergic Activities of Daidzein, a Metabolite of Puerarin and Daidzin Produced by Human Intestinal Microflora. Biological and Pharmaceutical Bulletin Vol. 25(2002) No.10, pp. 1328-1332.